Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MASP2 | O00187 | 1/20 | 0.32 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.32 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765806 | 0.86 | MAPK1 (0.36) | F2MAPK1MASP2NAMPTIDH1 | |
| SCHEMBL30765646 | 0.86 | MAPK1 (0.38) | F2MAPK1MASP2NAMPTIDH1 | |
| SCHEMBL30765871 | 0.85 | F2 (0.36) | F2MAPK1MASP2NAMPTMAPT | |
| SCHEMBL30765543 | 0.85 | ELANE (0.39) | F2MAPK1 | |
| SCHEMBL30765642 | 0.85 | MAPK1 (0.35) | F2MAPK1MASP2NAMPTIDH1 | |
| SCHEMBL30765516 | 0.84 | NTRK1 (0.35) | F2MAPK1 | |
| SCHEMBL30765885 | 0.84 | MAPK1 (0.34) | F2MAPK1NAMPTMAPT | |
| SCHEMBL30765625 | 0.84 | F2 (0.36) | F2MAPK1MAPT | |
| SCHEMBL30765919 | 0.83 | LMNA (0.34) | MAPK1MAPT | |
| SCHEMBL30766033 | 0.83 | LMNA (0.34) | MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |